| Project/Area Number |
16K15262
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Tokyo Metropolitan Institute of Medical Science |
|---|
Principal Investigator |
TAJIMA Youichi 公益財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (00300955)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 細胞融合 / 融合遺伝子 / 間葉系幹細胞 / dormancy / 癌不均一性 / 生体幹細胞 / 癌ゲノム / 癌悪性化 / 抗癌剤耐性 / 癌幹細胞 / 腫瘍 |
|---|
| Outline of Final Research Achievements |
Cell fusion likely drives tumor evolution by undermining chromosomal and DNA stability and by generating phenotypic diversity. However, whether a cell fusion event can initiate malignancy tumor evolution is unknown. We report that a fusion event between mesenchymal stem cells (MSCs) and bladder cancer cell line (UMUC-3) can initiate generation of fusion genes, cell transformation, and malignancy. We also reported that cell fusion induced the expression of genes including the X-gene associated with an aggressive phenotype. Hybrids depleted the X-gene suppressed tumor formations. These results suggested cell fusion event between MSCs and cancer cells is involve in tumor evolution by generation phenotypic diversity.
|
| Academic Significance and Societal Importance of the Research Achievements |
がんの増悪化に細胞融合が関与する可能性は100年前から指摘されていたが、明確に証明した研究は殆どない。我々は細胞融合により新たに融合遺伝子が形成される可能性を検討した。がんの増悪化に細胞融合が一端を担っていれば、細胞融合に特化した創薬開発に繋がる可能性が考えられる。
|
